NZYM B Novozymes A/S Class B

Resolutions from the Extraordinary Shareholders’ Meeting 2024

Resolutions from the Extraordinary Shareholders’ Meeting 2024



Company Announcement no. 10 March 4, 2024





Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made:



  • Adoption of Novonesis A/S as secondary name and amendment of the Articles of Association in accordance herewith
  • Election of Jesper Brandgaard as Vice Chair of the Board of Directors
  • Election of Lise Kaae, Kevin Lane and Kim Stratton as members of the Board of Directors


Following the extraordinary shareholders’ meeting, the Board of Directors consists of the following members:



  • Cornelis (Cees) de Jong, Chair
  • Jesper Brandgaard, Vice Chair
  • Heine Dalsgaard
  • Sharon James
  • Kasim Kutay
  • Lise Kaae
  • Kevin Lane
  • Morten Otto Alexander Sommer
  • Kim Stratton


Employee representatives:



  • Anne Breum
  • Anders Hentze Knudsen
  • Preben Nielsen
  • Jens Øbro
  • Karen Louise Lauesen, observer
  • Kim Ib Sørensen, observer
For further information on members of the Board of Directors, please go to



  

Attachment



EN
04/03/2024

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

November 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

November 7, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF Attachments

November 7, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis delivered 8% organic sales growth in the first nine months o...

Novonesis delivered 8% organic sales growth in the first nine months of 2025 Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.  COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%. Ester Baiget, President & CEO:  "I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and i...

November 6, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

8% organic sales growth after first nine months. Full-year organic sal...

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards. Ester Baiget, President & CEO: ”I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quar...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch